New insights into RAS in head and neck cancer

Sankar Jagadeeshan, Ofra Z. Novoplansky, Oded Cohen, Ina Kurth, Jochen Hess, Ari J. Rosenberg, Jennifer R. Grandis, Moshe Elkabets

Research output: Contribution to journalReview articlepeer-review


RAS genes are known to be dysregulated in cancer for several decades, and substantial effort has been dedicated to develop agents that reduce RAS expression or block RAS activation. The recent introduction of RAS inhibitors for cancer patients highlights the importance of comprehending RAS alterations in head and neck cancer (HNC). In this regard, we examine the published findings on RAS alterations and pathway activations in HNC, and summarize their role in HNC initiation, progression, and metastasis. Specifically, we focus on the intrinsic role of mutated-RAS on tumor cell signaling and its extrinsic role in determining tumor-microenvironment (TME) heterogeneity, including promoting angiogenesis and enhancing immune escape. Lastly, we summarize the intrinsic and extrinsic role of RAS alterations on therapy resistance to outline the potential of targeting RAS using a single agent or in combination with other therapeutic agents for HNC patients with RAS-activated tumors.

Original languageEnglish
Article number188963
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number6
StatePublished - Nov 2023


  • Head and neck cancer
  • Metastasis
  • Pre-clinical and clinical targeting
  • Progression
  • RAS activation
  • Therapy resistance

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'New insights into RAS in head and neck cancer'. Together they form a unique fingerprint.

Cite this